peptide immunogenicity peptide immunogenicity - UspImmunogenicity immunogenicity Understanding Peptide Immunogenicity: A Critical Factor in Therapeutic Development

New peptides The field of peptide therapeutics has seen significant growth, offering promising treatment options for a range of diseases.Assessing the immunogenicity risk of salmon calcitonin ... However, a critical factor that can potentially limit the efficacy and safety of these peptide-based therapeutics is peptide immunogenicity. This refers to a drug's ability to provoke an immune response, including the production of anti-drug antibodies (ADAs)2025年8月4日—Immunogenicity refers toa drug's ability to provoke an immune response, including the production of anti-drug antibodies (ADAs). While peptide .... Understanding and effectively managing peptide immunogenicity is paramount for successful drug development and safe patient use.

What is Peptide Immunogenicity?

Immunogenicity is broadly defined as the ability of a substance (autologous or foreign) to induce immune responses by the adaptive or innate immune system. In the context of therapeutic peptides, it means the body's immune system recognizes the administered peptide as foreign and mounts a response against it.Immunogenicity risk assessment of peptide-related ... This response can range from the production of antibodies to more complex cellular reactionsTechniques for Theoretical Prediction of Immunogenic .... While small peptides are important molecules for distinguishing proteins that originate within the body from those that are foreign, when introduced therapeutically, this natural function can become a challenge.

Factors Influencing Peptide Immunogenicity

Several factors contribute to the peptide immunogenicity of therapeutic agents. The inherent properties of the peptide itself play a significant roleExploring predictive features of peptide immunogenicity for .... These include:

* Peptide Sequence and Structure: Certain amino acid sequences are more likely to be recognized by the immune system. Some peptides are more immunogenic than others due to their T-cell epitope presentation. The three-dimensional structure, including folding and conformational flexibility, also impacts how T-cells recognize and respond to a peptide. The presence of easily accessible antigen peptides on the protein surface, particularly those in loop and turn regions, can increase immunogenicity.Computational immunology is a field of science that encompasses high-throughput genomic and bioinformatics approaches to immunology.

* Manufacturing Process: Advances in synthetic and recombinant manufacturing have expanded the possibilities for peptide productionImmunogenicity Assessments in Peptides. However, the increasing complexity of these processes may impact product quality attributes, including those related to immunogenicity. Complex peptide drugs can be produced through various methods, and the chosen method can influence the presence of impurities2017年7月26日—Look for antigen peptides that are accessible on the protein surfaceand somewhat conformationally flexible, that is, loop and turn regions on the protein..

* Impurities: Peptide drug impurities are a significant concern. These can arise from the manufacturing process and can include deletion, duplication, or aggregation of the intended peptide.Evaluation of the immunogenicity of peptide-drugs containing ... How peptide drug impurities can elicit unexpected immunogenicity is a key area of research. These impurities can be crucial in triggering an immune response even if the main peptide product has low immunogenicity. Assessing impurities to inform peptide immunogenicity risk is therefore a critical step.

Assessing and Managing Peptide Immunogenicity

Given the potential impact of immunogenicity on therapeutic outcomes, robust assessment strategies are essential.

* Immunogenicity Risk Assessment: A framework for performing immunogenicity risk assessment is crucial. This involves evaluating potential immunogenic triggers within the peptide product. The immunogenicity* of therapeutic peptides is a critical issue for their development and safe use in humans作者：K Achilleos·2025·被引用次数：20—A critical factor that can potentially limit the efficacy and safety of peptide- based therapeutics or biolog- ics isimmunogenicity, defined as an unintended .... Techniques such as in silico immunogenicity assessment of therapeutic peptides and computational immunology leverage bioinformatics approaches to predict potential immunogenic regions (epitopes) based on sequence and structure.作者：K Achilleos·2025·被引用次数：20—A critical factor that can potentially limit the efficacy and safety of peptide-based therapeutics or biologics isimmunogenicity. These computational approaches can identify peptide features relevant for prediction of immunogenicity作者：AE Mattei·2025—Discussion. TPT has a history of having lowimmunogenicityin the clinic, with only 2.8% of treated patients developing antidrug antibodies ....

* In Vitro and In Vivo Assays: Various assays are employed to evaluate immunogenicity. In vitro immunogenicity assays can assess the potential for immune cell activation or antibody production2020年9月20日—Peptiderelated (impurities related to the APIpeptide, such as deletion, duplication, etc.) Hence, generics should demonstrate differences in .... While most generic peptide drug impurities can be evaluated for immunogenicity risk using in silico tools, in vitro immunogenicity assays for evaluating generic peptide products are recommended when differences in impurity profiles are observed2022年9月20日—peptideshould be submitted as an ANDA depends largely on its impurity profile as compared to the impurity profile for thepeptideof rDNA ....

* T-cell Epitope Analysis: Understanding what the T cell sees and the effect on immune response is vital. T cell epitope and immunogenicity analysis for peptides and their impurities helps pinpoint specific regions that might trigger an immune reaction. Identifying immunogenic peptides (epitopes) forms a foundation for developing effective peptide-based vaccines or other immunomodulatory therapies.

* Regulatory Considerations: Regulatory bodies like the FDA have guidelines for assessing the immunogenicity of drug productsPeptide Immunogenicity Risk and Impurity Assessment .... The decision on whether a peptide should be submitted as an ANDA (Abbreviated New Drug Application) largely depends on its impurity profile as compared to the reference listed drug. Immunogenicity assessment of peptide products is recommended when differences in impurity profiles are observed.

Peptides as Potential Solutions

Interestingly, peptides are useful not only to overcome protein therapeutics immunogenicity but also to induce antigen-specific immune tolerance, preventing unwanted immune responses.Evaluation of the immunogenicity of peptide-drugs containing ... This dual nature highlights the intricate relationship between peptides and the immune system.

Conclusion

The peptide immunogenicity of therapeutic products is a complex but vital aspect of drug development.Peptide Immunogenicity Risk and Impurity Assessment ... By understanding the factors that influence immunogenicity, employing rigorous assessment strategies, and considering the role of impurities, researchers and manufacturers can mitigate risks and ensure the safe and effective delivery of peptide therapeutics. The ongoing advancements in immunogenicity analysis and predictive tools are crucial for realizing the full potential of peptide-based medicines作者：EC Jappe·2020—This thesis explores features ofpeptide immunogenicity, with a particular emphasis on the development of assays to probe pMHC stability which has been linked ....